Spinal Cord Stimulator Trial: Process, Success & Questions
Interventional Pain Management Physician, Chief of the Division of Pain Medicine at Good Samaritan University Hospital, and Founder of SpinePain Solutions. Dr. Sharma completed fellowship training in pain medicine at Johns Hopkins and has practiced interventional pain medicine since 2004.
A spinal cord stimulator trial is a temporary test of neuromodulation before a permanent system is considered. One or more temporary leads are positioned in the epidural space and connected to an external stimulator. For several days, the patient tracks whether stimulation provides meaningful improvement in pain and important daily activities.
The trial is useful, but it is not a guarantee. A good result supports considering permanent implantation; it cannot prove that the same relief will continue indefinitely. The most informative trial starts with a clear diagnosis, realistic expectations and measurable goals chosen before the leads are placed.
Many studies and insurers use at least 50% pain reduction as one trial benchmark. A sound clinical assessment also considers walking, sleep, daily activity, medication use, satisfaction and whether stimulation covered the intended painful region. The goals and any insurance threshold should be documented before the trial begins.
What Is a Spinal Cord Stimulator Trial?
A trial allows a patient to experience spinal cord stimulation without first receiving the fully implanted pulse generator. Temporary percutaneous leads are connected to an external system worn outside the body. The patient uses the prescribed programs at home and records the result. At the end of the trial, the temporary leads are removed.
The temporary trial is not the same procedure or recovery as permanent implantation. It does not create a permanent generator pocket, and temporary leads are not anchored in the same way as a permanent system. That difference is one reason the trial experience may not be reproduced exactly after implantation.
SCS and DRG Trials Are Related but Not Identical
Spinal cord stimulation generally targets dorsal spinal cord pathways and is often considered for broader back, limb, trunk or bilateral pain patterns. Dorsal root ganglion (DRG) stimulation targets one or more specific dorsal root ganglia and may be considered for selected focal neuropathic pain patterns. The diagnosis and pain distribution should determine which target is tested; one is not universally better.
Who May Be a Candidate for a Trial?
A trial is generally considered only after the broader spinal cord stimulation candidacy evaluation. Potential candidates usually have chronic, function-limiting pain, a reasonably established diagnosis, inadequate improvement with appropriate nonimplant treatment and no clearly preferable corrective treatment.
| Findings supporting consideration | Reasons to evaluate or treat first |
|---|---|
| Chronic, function-limiting neuropathic or appropriately selected refractory pain | Acute or improving pain, or an uncertain pain generator |
| Symptoms, examination and available imaging form a coherent diagnosis | Untreated compression, instability or another correctable structural problem |
| Appropriate lower-risk treatment has not provided adequate benefit | Reasonable diagnosis-specific treatment has not been attempted |
| Realistic pain and functional goals | Expectation of guaranteed or complete pain elimination |
| Acceptable infection, bleeding and procedural risk | Active infection or unresolved medical risk |
| Ability to manage the external trial system and record results | Practical, cognitive or adherence barriers that have not been addressed |
Psychosocial screening is not a claim that the pain is psychological. It helps evaluate expectations, coping, untreated behavioral conditions, substance-use concerns and practical factors that may affect safety, adherence and long-term outcomes.
How to Prepare for an SCS Trial
- Review medications: follow individualized instructions for anticoagulants, antiplatelet medicines, diabetes medicines and other prescriptions. Do not stop prescribed medication without direction from the appropriate clinician.
- Report infection concerns: notify the office about fever, a current infection, an open wound, a new antibiotic or illness before the procedure.
- Arrange transportation: sedation and facility policy may require an adult driver and supervision after the procedure.
- Record a baseline: document usual pain, walking or standing tolerance, sleep, rescue medication and two or three activities that pain normally limits.
- Clarify restrictions: obtain written guidance for bathing, driving, work, sleep position, bending, lifting and twisting.
- Know whom to call: keep the office and after-hours instructions available throughout the trial.
Never change a blood thinner, antiplatelet medicine, insulin or another important prescription based only on a web page. The prescribing clinician and procedure team must provide patient-specific instructions.
What Happens During Trial Lead Placement?
- The treatment team confirms the planned target, medications, consent and safety information.
- The patient is positioned, monitored and given local anesthetic. Sedation, when used, is individualized.
- Using imaging guidance, the physician advances one or more temporary leads through needles into the epidural space.
- The leads are tested and connected to an external stimulator. Programming depends on the system and may or may not produce tingling.
- The leads and dressings are secured, and the patient receives written restrictions, device instructions and contact information.
The number and location of leads, the amount of sedation, and the programming approach vary with the diagnosis, anatomy and neuromodulation target. The description above is a general overview, not a substitute for the treating physician’s procedure instructions.
During the Trial: Restrictions and Safety
Temporary leads can move before they are removed. Patients are commonly instructed to limit bending, lifting, twisting, reaching, strenuous exercise and other movements that place tension on the leads or external components. Exact restrictions vary and should be provided in writing.
- Keep the dressing and external equipment protected and dry as instructed.
- Do not remove or reinforce the dressing unless the treatment team directs you to do so.
- Do not drive if prohibited by the procedure instructions, sedation, pain, weakness or medication effects.
- Use only the controller adjustments and programs the team has authorized.
- Do not test function with unsafe lifting, vigorous exercise or another activity that violates trial restrictions.
- Record the same pain and functional measures each day so the response can be compared fairly.
When to Call the Treatment Team
Contact the treating team promptly for fever, spreading redness, drainage, an increasingly painful or swollen insertion site, a wet or disrupted dressing, severe positional headache, sudden loss of stimulation, uncomfortable stimulation that cannot be corrected with permitted adjustments, new numbness or new weakness. New bowel or bladder dysfunction, rapidly progressive neurological symptoms, chest pain or shortness of breath require urgent medical evaluation.
What Counts as a Successful SCS Trial?
At least 50% pain reduction is a commonly used threshold in research, clinical practice and coverage policies. It should not be treated as a universal guarantee or the only meaningful outcome. The 2023 multisociety consensus recommends evaluating trial response across multiple domains, including pain, function, medication use, satisfaction and tolerability.
| Domain | Baseline example | What to record during the trial |
|---|---|---|
| Usual pain | Average and worst pain before stimulation | Pain with the system on, at comparable times and activities |
| Walking or standing | Minutes or distance before stopping | Change in the same safe, permitted task |
| Sleep | Awakenings or hours slept | Ability to fall asleep, remain asleep or sleep in bed |
| Medication | Usual scheduled and rescue doses | Actual use without unsafe self-directed changes |
| Targeted activity | A specific task limited by pain | Whether the same task becomes meaningfully easier |
| Tolerability | Not applicable | Coverage, unwanted stimulation, controller use and satisfaction |
Medication should not be reduced simply to make the trial look successful. Any planned medication change should be discussed in advance so the result remains safe and interpretable.
Successful, Inconclusive or Unsuccessful?
| Result | How to frame it |
|---|---|
| Successful | The predefined pain and functional goals show convincing benefit, stimulation is tolerable, and no technical problem prevents interpretation. |
| Inconclusive | Lead movement, inadequate target coverage, equipment problems, illness, medication changes or insufficient safe activity prevents a fair assessment. |
| Unsuccessful | A technically adequate trial does not produce enough meaningful benefit or causes unacceptable stimulation or side effects. |
Why a Successful Trial Does Not Guarantee Permanent Results
A trial is a short test under unusual circumstances. Activity is restricted, the leads are temporary, and the permanent system may differ in lead position, anchoring, programming or generator features. Healing, later lead movement, a changing pain condition and a new pain generator can also affect long-term benefit.
The randomized TRIAL-STIM study found that a screening-trial strategy did not produce better patient outcomes than proceeding without a screening trial in the studied United Kingdom population. That finding does not mean an individual trial provides no useful information. It does show why a brief positive trial should not be described as a reliable promise of durable success. In the United States, trials also remain embedded in common clinical and coverage pathways.
A favorable trial supports a discussion of permanent implantation. The diagnosis, medical and psychosocial risks, technical result, functional improvement, patient preference, insurance requirements and long-term device responsibilities still need to be reviewed.
What Should I Ask Before an SCS or DRG Trial?
Before a spinal cord stimulation or dorsal root ganglion stimulation trial, understand the diagnosis being treated, why that target was selected, how benefit will be measured, what restrictions apply and how the temporary experience may differ from permanent implantation. Choose measurable goals before lead placement so the result is not judged from memory alone.
The trial should test more than a pain number. Decide which ordinary activities matter most, record the baseline and clarify what would make the trial successful, unsuccessful or technically inconclusive. The Print button above creates a paper or PDF copy of this page.
Diagnosis and Treatment Target
- What diagnosis and pain mechanism are we treating?
- Do my examination and imaging support that diagnosis?
- Is there untreated compression, instability or another correctable problem?
- Why is SCS, DRG stimulation or peripheral nerve stimulation the most appropriate target?
- Is this use within the system’s FDA-labeled indication?
- If it is off-label, what evidence and coverage limitations apply?
How Will We Measure Success?
- Which three functional activities should I test?
- What are my baseline pain and activity limits?
- What pain reduction does my insurer require?
- Will walking, sleep, medication use and quality of life also be considered?
- Should my medications remain stable so the trial can be interpreted?
- What would make the trial inconclusive rather than truly unsuccessful?
- Stand long enough to prepare a meal
- Walk a measured distance
- Sleep in bed instead of a recliner
- Wear a shoe or tolerate clothing over a painful CRPS region
- Climb stairs or complete another personally important permitted activity
- Use less rescue medication only under the agreed medication plan
Trial Procedure and Safety
- How long will the trial last and how many leads are anticipated?
- What local anesthetic and sedation will be used?
- Which medications require adjustment, and who will coordinate the change?
- How should I protect the dressing and external components?
- What bending, lifting, twisting, showering, work and driving restrictions apply?
- Which symptoms require an urgent call or emergency evaluation?
- Who should I contact after hours?
Questions About the Possible Permanent Implant
- Will the permanent lead type or location differ from the trial?
- Would the permanent implant use percutaneous or paddle leads?
- Where would the generator pocket be placed?
- Should I handle the charger before choosing a rechargeable system?
- Is the complete proposed system MR Conditional?
- Who will provide programming and long-term device support?
- What replacement, revision or removal procedures might eventually be needed?
SCS Versus DRG Trial Questions
| Question | SCS trial | DRG trial |
|---|---|---|
| Why this target? | Generally broader back, limb, trunk or bilateral coverage | Generally a smaller, anatomically coherent region |
| What should I test? | Overall pain, walking, sitting, sleep and broad goals | Coverage and function in the specific painful region |
| What evidence question matters? | Evidence for the diagnosis and proposed waveform | Established lower-limb CRPS indication versus potentially off-label use |
| What permanent details matter? | Lead type, generator, waveform and charging | Targeted DRG levels, number of leads and system restrictions |
What Happens When the Trial Ends?
The temporary leads are removed, usually without implanting the permanent generator during the same trial visit. The clinician reviews the daily record, pain response, functional change, medication use, stimulation coverage, tolerability, patient satisfaction and any technical concern.
- If the trial is successful: permanent implantation may be considered after the complete result, risks, device options and patient preferences are reviewed.
- If the trial is inconclusive: the team should identify whether lead movement, inadequate coverage, illness, medication change or another technical issue prevented a fair test.
- If the trial is unsuccessful: the diagnosis and alternatives should be reassessed rather than proceeding automatically to implantation.
A permanent implant requires a separate informed decision. Review rechargeable versus nonrechargeable battery options and permanent-implant recovery, MRI considerations, travel precautions, programming and long-term safety before choosing a system.
Risks and Important Limitations
Trial risks include infection, bleeding, epidural hematoma, dural puncture and spinal headache, nerve or spinal cord injury, temporary pain flare, lead movement, uncomfortable stimulation, skin irritation, equipment problems and inadequate coverage. Serious neurological complications are uncommon but possible.
A short trial cannot establish long-term durability. Activity restrictions may make the trial different from ordinary life. Medication changes, expectations, unusually low activity, lead movement and technical coverage can influence the result. A successful trial does not guarantee that medication can be stopped or that future reprogramming, revision or removal will never be needed.
Alternatives if the Trial Does Not Provide Enough Benefit
The appropriate next step depends on the diagnosis and why the trial did not succeed. Options may include:
- Further diagnostic evaluation or updated imaging
- Surgical assessment for a correctable structural lesion
- Medication, rehabilitation or interdisciplinary pain-care optimization
- Diagnosis-specific injections or radiofrequency treatment
- DRG stimulation for selected focal neuropathic pain patterns
- Peripheral nerve stimulation when pain maps to an appropriate peripheral nerve
- Continued nonimplant management when expected benefit does not justify device risk
Related Spinal Cord Stimulation Resources
Spinal Cord Stimulator Trial Evaluation on Long Island
A useful neuromodulation trial begins before the procedure. The diagnosis, treatment target, pain baseline, functional goals, restrictions, insurance requirements and possible permanent system should be discussed in advance.
At Amit Sharma MD, the evaluation is individualized to the pain mechanism, anatomy, medical risk, functional limitations and treatment goals. The recommendation may be an SCS trial, a DRG trial, another targeted treatment, further diagnostic work or continued nonimplant care.
Dr. Amit Sharma & our minimally invasive pain & spine team.
Spinal Cord Stimulator Trial FAQs
What happens during a spinal cord stimulator trial?
During a typical spinal cord stimulator trial, temporary leads are positioned through needles into the epidural space using imaging guidance and connected to an external stimulator. You then test the therapy at home for a limited period while tracking pain, function, sleep, medication use and satisfaction. The leads are removed after the trial.
How long does a spinal cord stimulator trial last?
A spinal cord stimulator trial usually lasts several days, but the exact length depends on the system, clinical circumstances, insurance requirements and physician protocol. Longer is not automatically better because externalized leads and dressings also create infection and lead-movement concerns.
What percentage of pain relief makes an SCS trial successful?
At least 50 percent pain reduction is a commonly used research and insurance benchmark, but it is not the only meaningful measure. Improvement in walking, sleep, daily activity, medication use and satisfaction should also be considered. The required threshold and personal goals should be clarified before the trial.
What should I ask before an SCS or DRG trial?
Ask which diagnosis and pain mechanism are being treated, why SCS or DRG was selected, which pain and functional goals will define success, what restrictions apply and how the temporary trial may differ from permanent implantation. You should also understand the proposed permanent lead and battery system, MRI eligibility, charging requirements, programming support, alternatives and what happens if the trial is unsuccessful or inconclusive.
What activities should I avoid during an SCS trial?
Patients are commonly told to avoid bending, lifting, twisting, strenuous activity and movements that could pull on the external components. The dressing generally must remain protected and dry. Driving, work, bathing and exercise instructions vary, so follow the specific restrictions provided by the treating team.
Can I shower during a spinal cord stimulator trial?
Usually the trial dressing and external components must be kept dry, so normal showering may not be permitted. Do not remove, replace or cover the dressing in a different way unless the treating team specifically instructs you to do so. Follow the written bathing instructions provided for your trial.
Does a successful SCS trial guarantee that the permanent implant will work?
No. A successful trial supports considering permanent implantation, but it cannot guarantee identical or lasting relief. The permanent lead configuration, healing, activity, programming, disease progression and changes in the pain generator can affect the result.
What happens if my spinal cord stimulator trial is unsuccessful or inconclusive?
An unsuccessful trial usually leads to reassessment rather than automatic implantation. If lead movement, inadequate coverage, a programming problem or another technical issue prevented a fair test, the result may be considered inconclusive. The next step may be further diagnostic evaluation, a different neuromodulation target or continued nonimplant treatment.
Selected References
- Shanthanna H, et al. Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain. Regional Anesthesia and Pain Medicine. 2023. Full text.
- Eldabe S, et al. Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? A randomized controlled trial. Pain. 2020. PubMed.
- Eldabe S, et al. Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility (TRIAL-STIM)? 36-month results from a randomized controlled trial. Neurosurgery. 2023. PubMed.
- West T, et al. Incidence of lead migration or misplacement in spinal cord stimulation: a systematic review and proportional meta-analysis of prospective studies and randomized clinical trials. Neuromodulation. 2023. PubMed.
